116 related articles for article (PubMed ID: 34863038)
1. The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes.
Hædersdal S; Lund A; Maagensen H; Nielsen-Hannerup E; Gasbjerg LS; Rosenkilde MM; Forman JL; van Hall G; Holst JJ; Knop FK; Vilsbøll T
Eur J Endocrinol; 2022 Jan; 186(2):207-221. PubMed ID: 34863038
[TBL] [Abstract][Full Text] [Related]
2. The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; Forman JL; Holst JJ; Knop FK; Vilsbøll T
Eur J Endocrinol; 2022 Oct; 187(4):507-518. PubMed ID: 35977072
[TBL] [Abstract][Full Text] [Related]
3. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.
Kelly RP; Garhyan P; Raddad E; Fu H; Lim CN; Prince MJ; Pinaire JA; Loh MT; Deeg MA
Diabetes Obes Metab; 2015 Apr; 17(4):414-22. PubMed ID: 25656305
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
Diabetes Care; 2016 Jul; 39(7):1241-9. PubMed ID: 26681715
[TBL] [Abstract][Full Text] [Related]
5. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; van Hall G; Holst JJ; Knop FK; Vilsbøll T
Diabetes; 2020 Dec; 69(12):2619-2629. PubMed ID: 33004472
[TBL] [Abstract][Full Text] [Related]
6. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects.
Knop FK; Konings E; Timmers S; Schrauwen P; Holst JJ; Blaak EE
Diabet Med; 2013 Oct; 30(10):1214-8. PubMed ID: 23663119
[TBL] [Abstract][Full Text] [Related]
7. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
Kazda CM; Frias J; Foga I; Cui X; Guzman CB; Garhyan P; Heilmann C; Yang JA; Hardy TA
Diabetes Obes Metab; 2017 Aug; 19(8):1071-1077. PubMed ID: 28191913
[TBL] [Abstract][Full Text] [Related]
8. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
[TBL] [Abstract][Full Text] [Related]
9. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Guzman CB; Zhang XM; Liu R; Regev A; Shankar S; Garhyan P; Pillai SG; Kazda C; Chalasani N; Hardy TA
Diabetes Obes Metab; 2017 Nov; 19(11):1521-1528. PubMed ID: 28371155
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of slowly and rapidly absorbed carbohydrates on postprandial glucose metabolism in type 2 diabetes mellitus patients: a randomized trial.
Ang M; Linn T
Am J Clin Nutr; 2014 Oct; 100(4):1059-68. PubMed ID: 25030779
[TBL] [Abstract][Full Text] [Related]
11. Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
Meier JJ; Ritter PR; Jacob A; Menge BA; Deacon CF; Schmidt WE; Nauck MA; Holst JJ
J Clin Endocrinol Metab; 2010 Aug; 95(8):4061-5. PubMed ID: 20501678
[TBL] [Abstract][Full Text] [Related]
12. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
13. A high-protein breakfast induces greater insulin and glucose-dependent insulinotropic peptide responses to a subsequent lunch meal in individuals with type 2 diabetes.
Park YM; Heden TD; Liu Y; Nyhoff LM; Thyfault JP; Leidy HJ; Kanaley JA
J Nutr; 2015 Mar; 145(3):452-8. PubMed ID: 25733459
[TBL] [Abstract][Full Text] [Related]
14. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease.
Idorn T; Knop FK; Jørgensen M; Holst JJ; Hornum M; Feldt-Rasmussen B
Nephrol Dial Transplant; 2014 Jan; 29(1):119-27. PubMed ID: 24078334
[TBL] [Abstract][Full Text] [Related]
15. Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.
Østoft SH; Bagger JI; Hansen T; Hartmann B; Pedersen O; Holst JJ; Knop FK; Vilsbøll T
Eur J Endocrinol; 2015 Aug; 173(2):205-15. PubMed ID: 25953829
[TBL] [Abstract][Full Text] [Related]
16. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
Beysen C; Murphy EJ; Deines K; Chan M; Tsang E; Glass A; Turner SM; Protasio J; Riiff T; Hellerstein MK
Diabetologia; 2012 Feb; 55(2):432-42. PubMed ID: 22134839
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial.
Perano SJ; Couper JJ; Horowitz M; Martin AJ; Kritas S; Sullivan T; Rayner CK
J Clin Endocrinol Metab; 2014 Jul; 99(7):2486-93. PubMed ID: 24670086
[TBL] [Abstract][Full Text] [Related]
18. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
[TBL] [Abstract][Full Text] [Related]
19. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
Baekdal M; Nielsen SW; Hansen CP; Storkholm JH; van Hall G; Hartmann B; Holst JJ; Vilsbøll T; Lund A; Knop FK
Diabetes Care; 2024 Jan; 47(1):71-80. PubMed ID: 37703527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
